NextGenREADING SHELF / FIVE SOURCES
Where our facts come from.
These peptide references support the distinctions in this guide. They cover approved product information, medicines made to order and concerns about research-only sales from the U.S. Food and Drug Administration (FDA). They are background reading, not a personal care plan.
TARGET STUDY / 02
GIP + GLP-1
01
Five sources, with a clear job for each.
FDA is short for the U.S. Food and Drug Administration. GLP-1 and GIP are names for hormone signals. The product information below describes specific approved medicines; it does not give FDA approval to a compounded version.
- FDA: what compounding means
Explains medicines made to order and how they differ from FDA-approved products.
- FDA: risks of compounded medicines
Explains that compounded medicines do not receive FDA approval before they are sold.
- FDA: concerns about unapproved GLP-1 drugs
Covers unapproved products, including retatrutide, sold with research-only labels.
- Semaglutide: approved product information
Records the GLP-1 target and the status of a specific approved semaglutide product.
- Tirzepatide: approved product information
Records the GIP and GLP-1 targets and the status of a specific approved tirzepatide product.
02
How to read the distinctions.
Compounding means making a medicine to order. Compounded medicines are not FDA-approved. The FDA sources explain that difference and the risks that come with products it has not reviewed before sale.
Retatrutide is investigational: still being studied in clinical trials. It is not FDA-approved and is not available by prescription. The research-sales source addresses unapproved retatrutide offered outside those trial conditions.
We do not use study results to predict an individual's outcome. A source about an approved product also cannot establish the contents or quality of a research-only product sold online.
Reading informs the question. Review informs care.
Promise prescribes semaglutide and tirzepatide now through licensed U.S. providers. A provider reviews every request and decides whether to prescribe. Not everyone qualifies.